Soligenix, Inc. COVID-19 Vaccine Candidate, CiVax, Could Be a More Viable Alternative to Moderna and PfizerNewsfile Corp • 12/09/20
Soligenix Announces Recent Accomplishments And Third Quarter 2020 Financial ResultsPRNewsWire • 11/12/20
Soligenix: One Approvable Drug And Another With Phase 3 Read Out Soon - $55M Valuation Won't LastSeeking Alpha • 10/26/20
Soligenix Announces Publication Demonstrating Thermostabilization of Filovirus Vaccine AntigensPRNewsWire • 09/15/20
Soligenix Announces Investor Webcast Event and Presentation Today: Advantages of the CiVax™ Program for Development of a Broadly Distributed Heat Stable COVID-19 VaccinePRNewsWire • 09/10/20
Soligenix Announces Investor Webcast Event: Advantages of the CiVax™ Program for Development of a Broadly Distributed Heat Stable COVID-19 VaccinePRNewsWire • 09/03/20
Soligenix Announces Recent Accomplishments And Second Quarter 2020 Financial ResultsPRNewsWire • 08/14/20
Soligenix: Multiple Shots On Goal, Strong Evidence Of Success, And Attractive ValuationSeeking Alpha • 07/28/20
Soligenix Issues Corporate Update - Highlights Important Catalysts for Second Half of 2020PRNewsWire • 07/20/20
Soligenix to Present at the MedInvest Infectious Disease and Immunology Investor ConferencePRNewsWire • 06/09/20
Soligenix Announces Recent Accomplishments And First Quarter 2020 Financial ResultsPRNewsWire • 05/15/20
Soligenix's Upcoming Catalyst For Pipeline Product SGX301 Could Offer A Nice Trade OpportunitySeeking Alpha • 04/20/20
